<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00279110</url>
  </required_header>
  <id_info>
    <org_study_id>R01DA018577</org_study_id>
    <nct_id>NCT00279110</nct_id>
  </id_info>
  <brief_title>Directly Administered HIV Therapy in Methadone Clinics</brief_title>
  <official_title>Directly Administered vs. Self-administered Antiretroviral Therapy in Methadone Clinics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether providing directly administered&#xD;
      antiretroviral therapy to HIV-infected who receive methadone therapy leads to better&#xD;
      treatment outcomes than if they take HIV medications on their own.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to conduct a randomized, unblinded, clinical trial of a medication adherence&#xD;
      intervention in opioid-dependent, HIV-infected participants who are initiating new&#xD;
      antiretroviral therapy, and who receive opioid agonist maintenance therapy with methadone or&#xD;
      buprenorphine in opioid treatment programs (OTPs) in Baltimore, MD. Randomization will be&#xD;
      stratified by study site and prior antiretroviral exposure. Two hundred participants will be&#xD;
      randomly assigned 1:1 self-administered antiretroviral therapy (SAT) or directly administered&#xD;
      antiretroviral therapy (DAART). Subjects assigned to DAART will take morning doses of&#xD;
      antiretroviral therapy with a nurse or medical assistant in a private room at the OTP. DAART&#xD;
      subjects will be transferred to self-administered therapy after 12 months. This is a 5 year&#xD;
      study and participants will be enrolled between month 6 and month 42 of the study. The&#xD;
      maximum follow-up for individual participants will be 18 months. Based on our pilot&#xD;
      experience we anticipate 50% of subjects will be women, 80% African American, with a median&#xD;
      age of 44 years. The following outcomes will be compared in the two study arms:&#xD;
&#xD;
        -  Suppression of the viral load (primary outcome)&#xD;
&#xD;
        -  Changes in CD4+ cell counts&#xD;
&#xD;
        -  The development of antiretroviral drug resistance&#xD;
&#xD;
        -  Retention to opioid agonist maintenance therapy, urine toxicology screens for drugs of&#xD;
           abuse, and self-reported drug and alcohol use&#xD;
&#xD;
        -  Self-reported adherence with therapy, retention to ART, and clinical and psychosocial&#xD;
           moderators of adherence&#xD;
&#xD;
        -  Electronically monitored medication adherence, using MEMS caps, in the first 2 months of&#xD;
           the study&#xD;
&#xD;
      Outcomes data will be obtained at study assessment visits at baseline, 3 months, 6 months, 12&#xD;
      months, and 18 months. Participants will provide contact information, take an&#xD;
      interviewer-administered survey, and provide blood and urine samples at study assessment&#xD;
      visits. MEMS cap data will be captured at 1 month and 2 months. Subjects will be compensated&#xD;
      for successful completion of study assessment visits and MEMS interrogations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV RNA &lt; 50 c/mL</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Log10 change in HIV RNA from baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV RNA &lt; 50 c/mL 6 mos. after intervention</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Log10 change in HIV RNA from baseline 6 months post intervention</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 cell count from baseline</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ART utilization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of antiretroviral resistance</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention to substance abuse treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine drug screen positivity in follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electronically monitored adherence</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>HIV Infections</condition>
  <condition>Heroin Dependence</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Directly administered antiretroviral therapy (DAART)</intervention_name>
    <description>Participants are observed taking HIV medications on days when they receive opioid agonist therapy.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eighteen years of age or older&#xD;
&#xD;
          2. Documented serologic evidence of HIV infection (positive ELISA and Western blot)&#xD;
&#xD;
          3. Identifiable medical provider, who is responsible for managing HIV treatment&#xD;
&#xD;
          4. Proof that ART has been prescribed and that patient has prescription medication&#xD;
             coverage&#xD;
&#xD;
          5. Nadir CD4+ cell count &lt; 350/mm3 or off-treatment HIV RNA &gt; 55,000 copies/ml if&#xD;
             asymptomatic and ART naive&#xD;
&#xD;
          6. Current plasma HIV RNA &gt; 500 copies/ml&#xD;
&#xD;
          7. Initiating ART for first time, reinitiating therapy after stopping, or changing&#xD;
             therapy due to virologic failure&#xD;
&#xD;
          8. ART with at least 3 agents, including a protease inhibitor, a non-nucleoside reverse&#xD;
             transcriptase inhibitor, or abacavir&#xD;
&#xD;
          9. Methadone or buprenorphine maintenance therapy &gt; 3 weeks, with no planned&#xD;
             detoxification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Need to use ART dosed more frequently than twice daily,&#xD;
&#xD;
          2. Need to use a liquid preparation of antiretroviral medication,&#xD;
&#xD;
          3. Documented triple-class antiretroviral resistance (defined below),&#xD;
&#xD;
          4. Participation in another study or program that includes directly observed therapy.&#xD;
&#xD;
          5. Use of ART regimens that are expressly discouraged in DHHS HIV clinical care&#xD;
             guidelines&#xD;
&#xD;
        Triple-class antiretroviral resistance will be defined according to IAS-USA interpretive&#xD;
        guidelines: NRTI class - 3 thymidine or non-thymidine-associated mutations (excluding the&#xD;
        M184V mutation) or a multi-nucleoside resistance mutation in reverse transcriptase; PI&#xD;
        class - 3 protease mutations, including 1 primary mutation; NNRTI class - 1 primary (K103N&#xD;
        or Y188L) or 2 secondary NNRTI-associated mutations in reverse transcriptase.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory M. Lucas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baltimore VA Drug Dependency Program</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Program for Alcohol and Other Drug Dependencies</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Man Alive, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hope Treatment Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Day Break Methadone Clinic</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mullen BA, Cook K, Moore RD, Rand C, Galai N, McCaul ME, Glass S, Oursler KK, Lucas GM. Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs. BMC Infect Dis. 2011 Feb 15;11:45. doi: 10.1186/1471-2334-11-45.</citation>
    <PMID>21324133</PMID>
  </reference>
  <results_reference>
    <citation>Lucas GM, Mullen BA, Galai N, Moore RD, Cook K, McCaul ME, Glass S, Oursler KK, Rand C. Directly administered antiretroviral therapy for HIV-infected individuals in opioid treatment programs: results from a randomized clinical trial. PLoS One. 2013 Jul 16;8(7):e68286. doi: 10.1371/journal.pone.0068286. Print 2013.</citation>
    <PMID>23874575</PMID>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>January 17, 2006</study_first_submitted>
  <study_first_submitted_qc>January 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2006</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <name_title>Gregory M. Lucas, MD PhD</name_title>
    <organization>Johns Hopkins University</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>Heroin dependence</keyword>
  <keyword>Methadone</keyword>
  <keyword>Buprenorphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

